INCY - INCYTE CORP
59.52
0.360 0.605%
Share volume: 2,184,439
Last Updated: 04-28-2025
Business Services/Services – Research, Development, Testing Labs:
-0.07%
PREVIOUS CLOSE
CHG
CHG%
$59.16
0.36
0.01%
Fundamental analysis
33%
Profitability
0%
Dept financing
42%
Liquidity
75%
Performance
52%
Performance
5 Days
0.93%
1 Month
-1.70%
3 Months
-19.26%
6 Months
-19.13%
1 Year
13.24%
2 Year
-21.00%
Key data
Stock price
$59.52
DAY RANGE
$58.44 - $59.60
52 WEEK RANGE
$51.75 - $83.95
52 WEEK CHANGE
$14.35
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
Company detail
CEO: Herve Hoppenot
Region: US
Website: incyte.com
Employees: 2,320
IPO year: 1993
Issue type: Common Stock
Market: XNAS
Industry: Business Services/Services – Research, Development, Testing Labs
Sector: Services
Region: US
Website: incyte.com
Employees: 2,320
IPO year: 1993
Issue type: Common Stock
Market: XNAS
Industry: Business Services/Services – Research, Development, Testing Labs
Sector: Services
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD) It also develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Recent news
